Medium 6.5Published Jun 18, 2026

CVE-2026-50034Apollo Pharmacy Blood Glucose Monitoring System APG-01 BT Cleartext Transmission of Sensitive Information

Updated under an hour ago (Oct 27, 2026, 1:10 PM ET)

Does this affect you?

It affects Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT). Add what you run to find out whether that includes you.

No exploitation reported and no EPSS estimate yet.

Do this next

Start free and add your stack

Free account, 1 product

Every CVE for Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT)

Exploited in the last 30 days

An attacker within BLE communication range can passively intercept wireless traffic and obtain sensitive health-related information, including glucose measurement values.

CVSS: 6.5 MEDIUM (v3.1, CNA)CVSS:3.1/AV:A/AC:L/PR:N/UI:N/S:U/C:H/I:N/A:N
Weakness (CWE): CWE-319
Known exploited: Not in CISA's KEV catalog
EPSS (exploitation in the next 30 days): Not loaded for this CVE
Assigned by: icscert
NVD analysis: Awaiting Analysis
Record last updated: Jun 22, 2026
First seen by InfoSec Signals: Oct 9, 2026

Affected products

Affected products

Apollo Pharmacy Blood Glucose Monitoring System (Model No. APG-01 BT) apollo_pharmacy:blood_glucose_monitoring_system_model_no_apg_01_bt (from the name)	0x0110_v1.1.0	CNA record

References

References

https://www.apollopharmacy.in/contact-us
https://www.cisa.gov/news-events/news/understanding-bluetooth-technology
https://www.cisa.gov/news-events/ics-medical-advisories/icsma-26-169-01
https://github.com/cisagov/CSAF/blob/develop/csaf_files/OT/white/2026/icsma-26-169-01.json

The CVE record on cve.org NVD's entry

The CVE record is authoritative. Products marked “from the name” were identified from the CNA's free-text names, not a CPE, and are matched less certainly. This product uses the NVD API but is not endorsed or certified by the NVD.